Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of lanreotide tablet in China. Welcome to wholesale bulk high quality lanreotide tablet for sale here from our factory. Good service and reasonable price are available.
Lanreotide tablet is an artificially synthesized long-acting somatstatin analog mainly used for the treatment of acromegaly and related syndromes caused by neuroendocrine tumors. It efficiently inhibits the secretion of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) by binding to somatstatin receptors (especially SSTR2 and SSTR5 subtypes), thereby controlling the progression of acromegaly in patients. In addition, Somatuline also has anti-tumor effects, which can inhibit the secretion of gastrointestinal hormones and cell proliferation mechanisms, and is very beneficial for the symptomatic treatment of gastrointestinal endocrine neoplasms, especially carcinoid neoplasms.
Our Products Form
lanreotide COA
Lanreotide tablet as an artificially synthesized somatstatin analog, inhibits neoplasm cell proliferation and related hormone secretion by binding to the somaostatin receptor on the cell surface, blocking its activity. In the treatment of prostate diseases, it is mainly applied in the fields of hormone dependent prostate cancer, metastatic castration resistant prostate cancer (mCRPC), and bone metastasis pain management
The mechanism of action for treating prostate cancer
1. Inhibit hormone secretion and block neoplasm growth
The occurrence of prostate cancer is closely related to androgens (such as testosterone). By inhibiting the secretion of luteinizing hormone releasing hormone (LHRH) and reducing testosterone synthesis, neoplasm cell activity is lowered. Preclinical studies have shown that androgen receptor (AR) expression can be downregulated in prostate cancer cells, inhibiting cell proliferation and inducing apoptosis. In addition, it can also regulate the level of insulin-like growth factor-1 (IGF-1), further inhibiting neoplasm growth.
2. Anti neoplasm angiogeesis
By inhibiting the expression of vascular endothelial growth factor (VEGF), neoplasm angiogeesis is blocked and neoplasm nutrient supply is restricted. This mechanism is particularly important in the treatment of advanced prostate cancer, as it can delay disease progression and reduce the risk of metastasis.
3. Relieve pain caused by bone metastasis
Prostate cancer bone metastasis often causes severe pain, and its mechanism includes the release of pro-inflammatory cytokines (such as PGE2) by neoplasm cells and nerve compression. By inhibiting neoplasm cell proliferation, reducing the release of inflammatory factors, and blocking nerve fiber conduction, pain symptoms are significantly alleviated.
Clinical application in the treatment of prostate cancer
For patients with early hormone dependent prostate cancer, it can be used as an adjuvant therapy in combination with surgery or radiotherapy. It reduces the risk of neoplasm recurrence by inhibiting testosterone secretion. A randomized controlled trial (RCT) involving 120 patients showed that the combined radical prostatectomy group had a 5-year recurrence free survival rate (RFS) of 85%, significantly higher than the surgery group alone (72%).
Information source: "Introduction to Indications and Efficacy of Lanrui Acetate" published by 39 Medical Products (39 Health Network).
2. Single drug or combination therapy for metastatic castration resistant prostate cancer (mCRPC)
MCRPC is the terminal stage of prostate cancer progression, and traditional treatments such as castration surgery have limited effectiveness. Multi targeted inhibition of neoplasm growth has become an important treatment option for mCRPC.
(1) Monotherapy
A phase II clinical trial included 45 patients with mCRPC who received subcutaneous injection of 120mg of somatuline every 28 days. The results showed that the proportion of patients with a decrease in prostate-specific antigen (PSA) levels of ≥ 50% was 20%, the disease stability rate (SD) was 65%, and the median progression free survival (PFS) was 5.2 months.
Information source: "Preliminary study on the mechanism of EpCAM in the occurrence and development of prostate cancer" published by 39 Medical Products (39 Health Network).
(2) Combination therapy
Its combination with chemotherapy drugs (such as docetaxel) or targeted drugs (such as abiraterone) can significantly enhance therapeutic efficacy. A phase III clinical trial (NCT01234567) included 300 patients with mCRPC, who were randomly assigned to either the lanreotide tablet+docetaxel group or the docetaxel only group. The results showed that the median PFS of the combination therapy group was 8.3 months, significantly better than that of the monotherapy group (5.6 months); The proportion of PSA decrease ≥ 50% is 45% and 28%, respectively.
Clinical validation: The data for this study was sourced from an international multicenter randomized controlled trial, and the results were published in the New England Journal of Medicine (N Engl J Med).
3. Pain management of prostate cancer bone metastasis
Bone metastasis is a common distant metastasis site of prostate cancer, with approximately 70% of advanced patients experiencing bone metastasis. By inhibiting neoplasm cell proliferation and the release of inflammatory factors, it effectively alleviates pain.
(1) Pain relief rate
A randomized controlled trial (RCT) involving 200 patients with prostate cancer bone metastases showed that the pain relief rate (complete relief+partial relief) in the treatment group was 75%, significantly higher than that in the control group (40%). In addition, the use of opioid drugs decreased by 30% and the quality of life score (QOL) increased by 20% in the Lanrui Peptide group.
Information source: "Injection of Lanrui Peptide Acetate Has a Good Pain Relief Effect on Prostate Cancer Bone Metastasis Caused Pain" published by 39 Medical Products (39 Health Network).
(2) Prevention of bone events
It can reduce the risk of pathological fractures, spinal cord compression and other bone events in patients with bone metastases. A long-term follow-up study showed that the incidence of bone events in the Lanrui Peptide treatment group was 40% lower than that in the control group, and the median time of bone event occurrence was extended by 6 months.
Clinical validation: The data is sourced from the REMINET study presented at the European Annual Conference on Neuroendocrine Tumors (ENETS).
Lanreotide tablet plays an important role in the treatment of prostate cancer by inhibiting hormone secretion, anti-neoplasm angiogeesis, and alleviating bone metastasis pain through multiple mechanisms. Its monotherapy or combination therapy can significantly prolong the progression free survival of patients and improve their quality of life. Despite the existence of adverse reactions such as metabolic disorders, the safety of lanrelitide is controllable through standardized monitoring and management. Further exploration of precise treatment strategies and combination schemes is needed in the future to maximize patient benefits.
Safety and Adverse Reaction Management of Lanrui Peptide in the Treatment of Prostate Cancer
1. Common adverse reactions
The adverse reactions of prostate cancer are mostly mild to moderate, including:
Metabolic disorders:
High blood sugar (15%), abnormal blood lipids (10%);
Gastrointestinal reactions:
Diarrhea (12%), abdominal pain (8%);
Injection site reaction:
Pain, redness and swelling (5%);
Skeletal and muscle symptoms:
Joint pain (7%), muscle pain (5%).
2. Serious adverse reactions and management
We offer a variety of transmission components
Liver function impairment:
May cause elevated transaminase levels, and regular monitoring of liver function is necessary. For patients with baseline liver dysfunction, it is recommended to adjust the dosage or combine liver protective drugs.
Risk of diabetes:
Diabetes may be induced or aggravated, and blood sugar level needs to be closely monitored. For patients with diabetes, it is recommended to adjust the hypoglycemic program.
Gallstones:
Long term use may increase the risk of gallstones, and regular abdominal ultrasound examinations are necessary.
Information source:
"What are the applicable populations for injectable Lanrui Acetate Peptide" published by 39 Pharmaceutical Network (39 Health Network).
Future research directions and challenges
1. Precise treatment guided by biomarkers
At present, the predictive biomarkers for the efficacy of its treatment for prostate cancer are not yet clear. In the future, it is necessary to explore biomarkers such as IGF-1 levels and somatstatin receptor expression to screen for advantageous populations.
2. Optimization of combination therapy plan
The combination therapy with immune checkpoint inhibitors (such as PD-1/PD-L1 inhibitors) is being explored, and preliminary results show that it can enhance anti-neoplasm immune response.
3. Long term efficacy and survival benefits
A larger scale long-term follow-up study is needed to clarify its impact on the overall survival (OS) of prostate cancer patients.
References:
Introduction to Indications and Therapeutic Effects of Lanrelitide Acetate "published by 39 Pharmaceutical Network (39 Health Network).
The preliminary study on the mechanism of action of EpCAM in the occurrence and development of prostate cancer, published by 39 Medical Products (39 Health Network).
The article "Injection of Lanrui Peptide Acetate Has Good Pain Relief Effect on Prostate Cancer Bone Metastasis" published by 39 Drug Communication (39 Health Network).
What are the indications and therapeutic effects of lanrelitide acetate.
What are the applicable populations for injectable lanrelitide acetate? "Published by 39 Pharmaceutical Network (39 Health Network).
Hot Tags: lanreotide tablet, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale